Cullinan Oncology, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. The filing was issued under the name Cullinan Oncology, Inc. The company is a clinical-stage oncology biopharmaceutical developer and reported no product revenue.
Financial results and position
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $52.1 million | $24.5 million |
| General and administrative expense | $10.7 million | $8.1 million |
| Total operating expenses / operating loss | $62.8 million | $32.7 million |
| Interest income | $4.5 million | $0.2 million |
| Net loss | $58.1 million | $12.9 million |
| Net loss attributable to Cullinan common stockholders | $58.0 million; $1.42 per share | $12.1 million; $0.27 per share |
| Net cash used in operating activities | $51.0 million | $21.9 million |
At March 31, 2023, cash and cash equivalents were $122.1 million, short-term investments $268.6 million, and long-term investments $110.4 million. The company reported $390.7 million of cash, cash equivalents and short-term investments, plus $112.8 million of long-term investments and interest receivable. Total assets were $515.0 million and total liabilities $29.3 million; liabilities included $4.7 million of operating lease obligations. No conventional borrowing balance is clearly reported; accrued expenses included $1.8 million for a convertible note and interest. Operating cash use increased year over year. Revenue-based margins are not meaningful because the company had no product sales.
Material changes and unusual items
- R&D expense more than doubled, largely reflecting $25.0 million upfront for the CLN-418 license, plus clinical supply costs. CLN-418 accounted for $26.9 million of Q1 R&D expense.
- Other program spending shifted: zipalertinib R&D declined to $5.7 million from $7.9 million, while CLN-049 and CLN-619 spending increased. G&A rose by $2.5 million, primarily due to headcount and professional services.
- Q1 2022 net loss was reduced by a $19.6 million income tax benefit; no tax benefit or expense was recorded in Q1 2023. The company maintained a full valuation allowance on remaining deferred tax assets.
- In January 2023, holders exchanged 6.475 million common shares for 647,500 Series A preferred shares, each convertible into 10 common shares, subject to ownership limits. Common shares outstanding were 39.34 million at quarter-end.
- In May 2023, the company established a Cowen at-the-market program allowing sales of up to $125 million of common stock. It said the prior SVB Securities program was terminated before any shares were sold.
Liquidity, outlook and risks
Management expected available cash, cash equivalents and investments to fund operations and capital needs for at least 12 months from issuance of the financial statements. It also cautioned that estimates depend on assumptions and available capital could be used sooner than expected. The company expects operating losses and cash needs to continue, with expenses rising as programs advance; it does not expect product-sales revenue in the near term, if at all.
The portfolio included six clinical-stage candidates. Zipalertinib is co-developed with Taiho, with development costs shared equally; enrollment continued at 100 mg twice daily in its pivotal Phase 2b trial, while further enrollment in the 150 mg twice-daily cohort was discontinued following a safety review committee recommendation. CLN-978 and CLN-617 had FDA-cleared INDs. Management expected initial CLN-619 clinical data in June 2023 and CLN-418 data in 2024. Key risks include clinical safety and efficacy, trial enrollment and timing, reliance on third-party manufacturers and trial providers, regulatory outcomes, intellectual property, and the need for future financing. The filing reported no material legal proceedings and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether clinical progress, enrollment, safety findings and anticipated data timelines for the pipeline remain on track.
- Actual cash burn and investment balances versus management’s stated runway, including the effect of future development spending and milestone obligations.
- Any sales under the $125 million ATM program and resulting dilution, including potential conversion of preferred shares.
- CLN-418’s development costs and potential contingent obligations under the Harbour agreement: up to $148 million in development and regulatory milestones, up to $415 million in sales milestones, and tiered royalties.
- Whether the 2022 tax benefit and the quarter’s unusual $25 million license charge affect comparisons of underlying operating trends.